CompletedPHASE1, PHASE2NCT01034631
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoosier Cancer Research Network
- Principal Investigator
- Thomas Hutson, D.O.Hoosier Cancer Research Network
- Intervention
- Everolimus(drug)
- Enrollment
- 154 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2016
Study locations (30)
- Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
- Genesis Cancer Center, Hot Springs, Arkansas, United States
- Providence Health System: Roy and Patricia Disney Family Cancer Center, Burbank, California, United States
- Compassionate Cancer Care Medical Group, Inc., Corona, California, United States
- Compassionate Cancer Care Medical Group, Corona, California, United States
- City of Hope, Duarte, California, United States
- Robert A. Moss, M.D., FACP, Inc., Fountain Valley, California, United States
- California Cancer Associates for Research and Excellence, Fresno, California, United States
- Marin Specialty Care, Greenbrae, California, United States
- Good Samaritan Hospital, Los Angeles, California, United States
- UCLA Med - Hematology & Oncology, Los Angeles, California, United States
- Compassionate Cancer Care Medical Group, Riverside, California, United States
- American Institute of Research, Whittier, California, United States
- Centura Health Research Center, Denver, Colorado, United States
- Western Oncology & Hematology, Golden, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bionomics Limited
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01034631 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma